Log In
Print this Print this

Keyzilen, esketamine (AM-101)

  Manage Alerts
Collapse Summary General Information
Company Auris Medical Holding AG
DescriptionIntratympanicly injected non-competitive NMDA receptor antagonist
Molecular Target NMDA receptor
Mechanism of ActionNMDA receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationTinnitus
Indication DetailsTreat acute and post-acute inner ear tinnitus following traumatic cochlear injury or otitis media; Treat acute peripheral (inner ear) tinnitus; Treat post acute inner ear tinnitus
Regulatory Designation U.S. - Fast Track (Treat acute peripheral (inner ear) tinnitus);
U.S. - Special Protocol Assessment (Treat acute peripheral (inner ear) tinnitus)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today